Stream
Stories
-
Incyte posts results of Phase 3 povorcitinib trial in hidradenitis suppurativa
The study enrolled 619 participants and completed its primary phase on January 7, 2025. Results were first posted on ClinicalTrials.gov on November 5, 2026.
-
Gilead posts results of Phase 3 ARTISTRY-2 study of BIC/LEN versus B/F/TAF
Results for the Phase 3 ARTISTRY-2 study were first posted on ClinicalTrials.gov on November 5, 2026. The study enrolled 577 participants and completed primary data collection on October 27, 2025.
-
Acepodia announces first patient dosed in Phase 1 trial of ACE723
The first patient was dosed at a clinical trial site in China on November 5, 2026, marking the first human exposure of ACE723, a GPC3-targeted dual-payload antibody-drug conjugate. ACE723 received IND clearance from the FDA and China's NMPA in September 2026 and TFDA approval in October 2026.
-
FDA classifies wearable vibration device for orthopedic use as class II
The FDA finalized an order classifying the wearable vibration device for orthopedic use into class II with special controls, stating the classification will provide a reasonable assurance of the safety and effectiveness of the device. The agency said the action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
-
FDA classifies mild cognitive impairment prognostic software as class II
The FDA issued a final order classifying the prognostic assessment software of mild cognitive impairment into class II with special controls, as stated in the Federal Register. The order notes that this classification should provide reasonable assurance of safety and effectiveness and may enhance patient access by reducing regulatory burdens.
-
CMS finalizes CY 2027 Medicare Physician Fee Schedule rule
The Centers for Medicare & Medicaid Services published a final rule on November 4, 2026 that finalizes policy changes for Medicare payments under the Physician Fee Schedule effective Jan. 1, 2027. The rule includes a +0.75% conversion factor for qualifying APM participants and a +0.25% factor for non-qualifying participants, with overall payment reductions of 1.83% and 2.31% respectively compared to CY 2026.
-
CMS finalizes 2027 Home Health payment rule, adds enrollment revocation changes
On November 4, 2026, the Centers for Medicare & Medicaid Services issued a final rule that updates the Home Health Prospective Payment System for CY 2027, including a 2.1% payment increase ($365 million) and a 0.3% fixed-dollar-loss adjustment ($50 million). The rule also makes all revocation grounds retroactive.
-
CMS finalizes broad Medicare integrity changes in home health final rule
CMS finalized a CY 2027 Home Health Prospective Payment System final rule that is expected to save taxpayers approximately $82 million annually by strengthening its ability to recover Medicare payments from noncompliant providers and suppliers. The rule also shortens the OASIS data submission deadline from 135 days to 45 days, potentially reducing the public reporting lag by up to three months.
-
Sanofi tops 2026 CNS Summit Digital Innovation Index
The index ranks the top 30 pharmaceutical companies on digital innovation, using publicly reported initiatives and investments from July 2025 through July 2026. The top 10 list includes Eli Lilly, AstraZeneca, Chugai, Roche, Bristol Myers Squibb, Novo Nordisk, Johnson & Johnson, Boehringer Ingelheim and Merck KGaA.
-
Innovent registers Phase III trial of sintilimab with LCCRT in locally advanced rectal cancer
The study, led by Innovent Biologics (Suzhou) Co. Ltd., plans to enroll 500 participants with locally advanced rectal cancer and is planned to start on November 25, 2026. It evaluates sintilimab combined with long-course concurrent chemoradiotherapy followed by Capeox consolidation chemotherapy versus the same regimen without sintilimab.
-
Boehringer Ingelheim registers Phase 3 study of verducatib in bronchiectasis
The study, NCT07915219, plans to enroll 1500 participants and begin on January 11, 2027, to evaluate long-term safety and efficacy of verducatib in patients with bronchiectasis. Participants can stay in the study for up to 1 year and 9 months, with primary completion projected for July 31, 2029.
-
Colgate Palmolive registers Phase 3 trial of stannous fluoride vs regular fluoride toothpaste
The study was first posted on ClinicalTrials.gov on November 4, 2026 and currently has 84 participants enrolled. It is planned to complete primary outcomes in April 2027.